Treatment to improve donor kidney function after transplant
Part of Heart & circulation clinical trials.
This trial tests a new liquid treatment (iCM012) that is applied to a donor kidney before transplantation. The goal is to improve how well the kidney works after it is transplanted.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old and have chronic kidney disease
- Have been on dialysis for more than 12 months
- Be waiting for your first kidney transplant
- The donated kidney must come from a donor aged 55–75 (controlled donation after circulatory death)
- Must not have had any previous organ or cell transplant
- Must not be highly sensitized (have a high level of antibodies against donor tissue)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to help your body accept the transplanted kidney without needing as many strong anti-rejection drugs. It uses special cells from your living donor, which may lower the risk of rejection and reduce side effects.
This study tests whether giving a special mix of donor immune cells along with immune-suppressing medicines right after a kidney transplant can help the body accept the new kidney without long-term anti-rejection drugs. It aims to reduce the need for daily transplant medications.
This trial tests a machine method that keeps a donated kidney working “outside the body” so it may be better repaired before transplant. It is designed for certain first/second kidney transplants using specific donor types and storage methods.
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
This Phase 2 trial studies a treatment using immune cells made from your living donor, given around the time of kidney transplant. It aims to improve transplant safety and outcomes by adjusting the immune response to the new kidney.
This early-phase trial tests a stem cell transplant from a donor who is an extremely close match, given to people who are about to receive a kidney transplant from the same donor. The goal is to improve how well the new kidney works by resetting the immune system to better accept the transplant.
Hear when a new Ischemia Reperfusion Injury trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.